.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PRODIGE 24 trial compared adjuvant modified FOLFIRINOX with gemcitabine in patients who had undergone resection for pancreatic ductal adenocarcinoma and had recovered sufficiently for postoperative chemotherapy. The trial established a major improvement in disease-free survival with FOLFIRINOX and also demonstrated a meaningful overall-survival advantage during longer follow-up. The findings helped shift postoperative pancreatic-cancer care toward more intensive combination chemotherapy for fit patients rather than gemcitabine alone. Clinically, the value of the study extends beyond the drug comparison. It reinforces the principle that surgery is only one component of treatment for pancreatic cancer, with systemic therapy playing an essential role in controlling recurrence risk. At the same time, FOLFIRINOX has substantial toxicity, so patient fitness, postoperative recovery, performance status and access to experienced oncology support influence whether the regimen is appropriate. For surgeons, the trial supports early multidisciplinary planning so that referral, resection and postoperative systemic treatment are coordinated from the outset.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PRODIGE 24 trial compared adjuvant modified FOLFIRINOX with gemcitabine in patients who had undergone resection for pancreatic ductal adenocarcinoma and had recovered sufficiently for postoperative chemotherapy. The trial established a major improvement in disease-free survival with FOLFIRINOX and also demonstrated a meaningful overall-survival advantage during longer follow-up. The findings helped shift postoperative pancreatic-cancer care toward more intensive combination chemotherapy for fit patients rather than gemcitabine alone. Clinically, the value of the study extends beyond the drug comparison. It reinforces the principle that surgery is only one component of treatment for pancreatic cancer, with systemic therapy playing an essential role in controlling recurrence risk. At the same time, FOLFIRINOX has substantial toxicity, so patient fitness, postoperative recovery, performance status and access to experienced oncology support influence whether the regimen is appropriate. For surgeons, the trial supports early multidisciplinary planning so that referral, resection and postoperative systemic treatment are coordinated from the outset.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
